Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk?

Choi, Audrey H.; Ji, Liang; Babcock, Blake D; Ramos, Vicente; Kwong, Mei Li M.; Morgan, John; Selleck, Matthew J.; Langridge, William H. R.; DeLeon, Marino; Wall, Nathan R.; Lum, Sharon S.; Pigazzi, Alessio; Dayyani, Farshid; Senthil, Maheswari

doi:10.1002/jso.26210

Cited by 9 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After title and abstract screening, 38 studies were considered potentially eligible. After full text screening, seventeen studies were included [ 12 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. The study flowchart and reasons for exclusion are shown in Figure 1 and Appendix B .…”

Section: Resultsmentioning

confidence: 99%

“…The study flowchart and reasons for exclusion are shown in Figure 1 and Appendix B . In sixteen studies, information on incidence numbers of synchronous gastric peritoneal metastases was provided [ 12 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. Risk factors for gastric peritoneal metastases were reported in four studies [ 15 , 16 , 17 , 18 ].…”

Section: Resultsmentioning

confidence: 99%

“…In sixteen studies, information on incidence numbers of synchronous gastric peritoneal metastases was provided [ 12 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. Risk factors for gastric peritoneal metastases were reported in four studies [ 15 , 16 , 17 , 18 ]. Survival was also reported in four studies [ 12 , 15 , 16 , 28 , 29 ].…”

Section: Resultsmentioning

confidence: 99%

“…Of all included studies, five studies were population-based studies [ 12 , 15 , 16 , 17 , 18 ], six studies were observational cohort studies [ 19 , 20 , 21 , 22 , 23 , 24 ] and six studies reported surgical cohorts of patients who underwent a staging laparoscopy [ 25 , 26 , 27 , 28 , 29 , 30 ]. Study characteristics and outcome measures of all studies are presented in Table 1 A,B and Table 2 .…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival

Rijken

Lurvink

Luyer

et al. 2021

JCM

View full text Add to dashboard Cite

The peritoneum is a common metastatic site in gastric cancer. This systematic review provides an overview of the incidence, risk factors and survival of synchronous peritoneal metastases from gastric cancer. A systematic search was performed to identify studies wherein the incidence, risk factors and survival of gastric cancer with peritoneal metastases were investigated. Of all 38 potentially eligible studies, 17 studies were included based on the eligibility criteria. The incidence of synchronous gastric peritoneal metastases was reviewed for population-based studies (10–21%), for observational cohort studies (2–15%) and for surgical cohort studies (13–40%). Potential risk factors for synchronous gastric peritoneal metastases were younger age, non-cardia gastric cancer, female sex, signet ring cell carcinoma, diffuse type histology or linitis plastica, T4 stage, Hispanic ethnicity and more than one metastatic location. Synchronous peritoneal metastases are commonly diagnosed in patients with gastric cancer with an incidence up to 21% in recent population-based studies. Furthermore, prognosis of patients with gastric peritoneal metastases is poor with median overall survival ranging from 2 to 9 months. The high incidence and poor prognosis require intensive research on diagnostic features and effective treatment options to improve survival.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival

Rijken

Lurvink

Luyer

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…There are vast documented disparities in clinical and patient‐reported outcomes across most malignancies, with overwhelming evidence suggesting that HLs are at a critical disadvantage. Hispanics and Latinos, specifically, present with more advanced disease and have a poorer prognosis for several different cancers relative to NHWs [10–16].…”

Section: Social Determinants Of Health In Hispanic and Latinos: Effects On Cancer Outcomesmentioning

confidence: 99%

Overcoming Disparities in Cancer: A Need for Meaningful Reform for Hispanic and Latino Cancer Survivors

et al. 2021

View full text Add to dashboard Cite

Hispanic and Latino (HL) cancer survivors are at a critical disadvantage compared to non-Hispanic White (NHWs) patients regarding sociodemographic adversities and access to equitable treatment options. By 2030, there will be about four million HL cancer survivors in the US, representing nearly 20% of survivors in this country. Hispanics and Latinos are subjected to significant challenges in accessing and receiving equitable care relative to NHWs. Hispanics and Latinos also experience lower rates of health insurance and financial resources, limiting healthcare options. These disparities often originate from disparate social determinants of health including lower funding for education and school programs, greater neighborhood stressors and violence, lower access to healthy and affordable food, and greater barriers to community health/ exercise opportunities. Even among HLs with proper access to healthcare, they experience disparate treatment options including low inclusion in clinical trials and/or access to experimental therapies. A solution to these barriers necessitates complex and systemic changes that involve, for example, investing in public health programs, increasing the diversity and cultural awareness of the medical workforce, and promoting research opportunities such as clinical trials that are inclusive of HLs. Only through meaningful reform will equitable cancer care be available for all in the US regardless of racial and/or ethnic background. This manuscript reviews some of the critical social determinants of health and biases relevant to HL cancer survivors and provides recommendations for achieving cancer health equity. The Oncologist 2021;9999:• • Implications for Practice: Hispanics and Latinos experience a significant and often disproportionate cancer-related burden compared to non-Hispanic and Latino Whites and other racial/ethnic groups. Meaningful reform to achieve health equity in oncology should focus on approaches to gaining trust among diverse patients, cultural and community sensitivity and engagement in oncology care and research, diversifying the workforce, and improving inclusion in clinical trial participation. Taken together, these recommendations can lead to exemplary and equitable care for all patients.

show abstract

Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival

Rijken,

Pape,

Simkens

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

The aims of this study were to investigate incidence, risk factors and treatment of synchronous or metachronous peritoneal metastases (PM) from gastric cancer and to estimate survival of these patients using population‐based data. Patients diagnosed with gastric cancer in 2015 to 2016 were selected from the Netherlands Cancer Registry. The incidence of synchronous and metachronous PM were calculated. Multivariable regression analyses were performed to identify factors associated with the occurrence of PM. Treatment and survival were compared between patients with synchronous and metachronous PM. Of 2206 patients with gastric cancer, 741 (34%) were diagnosed with PM. Of these, 498 (23%) had synchronous PM. The cumulative incidence of metachronous PM in patients who underwent potentially curative treatment (n = 675) was 22.8% at 3 years. A factor associated with synchronous and metachronous PM was diffuse type histology. Patients diagnosed with synchronous PM more often received systemic treatment than patients with metachronous PM (35% vs 18%, respectively, P < .001). Median overall survival was comparable between synchronous and metachronous PM (3.2 vs 2.3 months, respectively, P = .731). Approximately one third of all patients with gastric cancer are diagnosed with PM, either at primary diagnosis or during 3‐year follow‐up after potentially curative treatment. Patients with metachronous PM less often received systemic treatment than those with synchronous PM but survival was comparable between both groups. Future trials are warranted to detect gastric cancer at an earlier stage and to examine strategies that lower the risk of peritoneal dissemination. Also, specific treatment options for patients with gastric PM should be further investigated.

show abstract

Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk?

Cited by 9 publications

References 23 publications

The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival

The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival

Overcoming Disparities in Cancer: A Need for Meaningful Reform for Hispanic and Latino Cancer Survivors

Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival

Contact Info

Product

Resources

About